English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Novel poly(ADP-ribose)polymerase (PARP)-1 inhibitors containing, the 4-(benzylideneamino)- N -(quinolin-8-yl)benzamide moiety, were designed and synthesized. The docking study revealed that the designed compounds possess significant to moderate interaction with the targeted enzyme PARP1. Among them compound  3d  (−52.04 K/cal) and  3e  (−50.234 K/cal) showed similar Glidescore compared to Olaprib (−57.76 K/cal). Some of the synthesized compounds displayed good PARP-1 inhibitory activity, and among them,  3d  and  3e  were the most potent one. Enzyme inhibitory assay indicated that the compounds  3d, 3e, 3i  and  3o  exhibited an enzyme inhibitory activity against PARP-1 enzyme similar to that of olaparib. All the synthesized compounds were screened for their  in vitro  anticancer activity against MCF-7 and MDA-MB-232 cell lines. Among them, compound  3d  (60.63 μg/mL and 56.38 μg/mL) and  3e  (3 68.03 μg/mL and 54.42 μg/mL) were the most potent ones. In addition, ADMET prediction results indicated that these compounds might be less toxic and display more interesting pharmacokinetic properties.

Design, Synthesis, and In - Vitro Biological Evaluation of PARP-1 Inhibitors Based on a 4-(Benzylideneamino)-N-(Quinolin-8-yl)Benzamide Scaffold